Association of nirmatrelvir for acute SARS‐CoV‐2 infection with subsequent Long COVID symptoms in an observational cohort study
MS Durstenfeld, MJ Peluso, F Lin… - Journal of Medical …, 2024 - Wiley Online Library
Oral nirmatrelvir/ritonavir is approved as treatment for acute COVID‐19, but the effect of
treatment during acute infection on risk of Long COVID is unknown. We hypothesized that …
treatment during acute infection on risk of Long COVID is unknown. We hypothesized that …
The effectiveness of novel oral antiviral treatment for non-hospitalized high-risk patients with COVID-19 during predominance of omicron XBB subvariants
Objectives This study investigated the association between nirmatrelvir plus ritonavir (NMV-
r) or molnupiravir and the outcomes of non-hospitalized high-risk patients with COVID-19 …
r) or molnupiravir and the outcomes of non-hospitalized high-risk patients with COVID-19 …
Is Paxlovid Still Worth It?
JS Faust, G Meyerowitz-Katz - Clinical Infectious Diseases, 2024 - academic.oup.com
Novel therapeutics receive regulatory approval when studies have adequately
demonstrated safety and efficacy. Whether therapeutics are covered by medical insurers …
demonstrated safety and efficacy. Whether therapeutics are covered by medical insurers …
Clinical Effectiveness of Ritonavir-Boosted Nirmatrelvir—A Literature Review
S Paltra, TOF Conrad - Advances in Respiratory Medicine, 2024 - mdpi.com
Highlights What are the main findings? Nirmatrelvir/Ritonavir, an oral treatment for COVID-
19, effectively reduces the risk of progressing to a more severe disease state for both the …
19, effectively reduces the risk of progressing to a more severe disease state for both the …